Outset Medical, Inc. (NASDAQ:OM – Get Rating) hit a new 52-week low during mid-day trading on Tuesday after Cowen lowered their price target on the stock from $60.00 to $33.00. The company traded as low as $14.08 and last traded at $14.08, with a volume of 11888 shares trading hands. The stock had previously closed at $20.41.
Other equities research analysts have also recently issued research reports about the stock. Bank of America started coverage on shares of Outset Medical in a research note on Wednesday, March 2nd. They set a “buy” rating on the stock. Stifel Nicolaus reduced their price objective on shares of Outset Medical from $55.00 to $30.00 in a research report on Tuesday. Finally, Morgan Stanley upgraded shares of Outset Medical from an “equal weight” rating to an “overweight” rating and reduced their price objective for the company from $55.00 to $50.00 in a research report on Thursday, February 17th.
In other news, CEO Leslie Trigg sold 30,000 shares of the business’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $20.95, for a total transaction of $628,500.00. Following the completion of the sale, the chief executive officer now directly owns 292,073 shares of the company’s stock, valued at $6,118,929.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel John L. Brottem sold 1,400 shares of the company’s stock in a transaction dated Thursday, March 17th. The stock was sold at an average price of $40.46, for a total transaction of $56,644.00. The disclosure for this sale can be found here. Insiders have sold 166,141 shares of company stock valued at $6,337,694 over the last ninety days. 4.00% of the stock is owned by insiders.
Crypto can be difficult to invest in during a bear market…
Especially when prices tend to be much more volatile as investors see their assets lose value.
Don’t try to guess your way through it… check out these three cryptocurrencies before you make another trade.
A number of institutional investors have recently made changes to their positions in OM. Advisor Group Holdings Inc. raised its holdings in Outset Medical by 253.6% in the fourth quarter. Advisor Group Holdings Inc. now owns 1,326 shares of the company’s stock worth $61,000 after purchasing an additional 951 shares in the last quarter. Fieldpoint Private Securities LLC bought a new position in Outset Medical in the fourth quarter worth about $67,000. IFP Advisors Inc acquired a new position in shares of Outset Medical during the fourth quarter valued at about $82,000. US Bancorp DE increased its holdings in shares of Outset Medical by 286.7% during the first quarter. US Bancorp DE now owns 2,711 shares of the company’s stock valued at $123,000 after acquiring an additional 2,010 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of Outset Medical by 297.9% during the second quarter. Royal Bank of Canada now owns 3,259 shares of the company’s stock valued at $163,000 after acquiring an additional 2,440 shares in the last quarter.
The company has a debt-to-equity ratio of 0.09, a current ratio of 7.72 and a quick ratio of 6.84. The stock has a market cap of $669.06 million, a price-to-earnings ratio of -4.76 and a beta of 2.13. The company’s fifty day moving average price is $31.42 and its 200-day moving average price is $38.13.
Outset Medical (NASDAQ:OM – Get Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($0.78) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.78). The firm had revenue of $30.55 million for the quarter, compared to the consensus estimate of $30.35 million. Outset Medical had a negative net margin of 125.91% and a negative return on equity of 35.58%. On average, sell-side analysts forecast that Outset Medical, Inc. will post -2.98 earnings per share for the current fiscal year.
Outset Medical Company Profile (NASDAQ:OM)
Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Outset Medical, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Outset Medical wasn’t on the list.
While Outset Medical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.